Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
In Guru Portfolios
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
About
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of SEER is 4.00 and suggests 83.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr